中欧医疗创新股票A股票持仓前十占比合计75.62%，分别为：药明合联（10.35%）、科伦博泰生 （10.15%）、药明生物（9.82%）、药明康德（9.60%）、康方生物（7.89%）、康龙化成（7.01%）、 恒瑞医药（6.20%）、凯莱英（5.87%）、百利天恒（4.70%）、泰格医药（4.03%）。 公开资料显示，中欧医疗创新股票A基金成立于2019年2月28日，截至2025年3月31日，中欧医疗创新股 票A规模46.75亿元，基金经理为葛兰。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年3月31日起至2016年4月22日)、中欧瑾和灵活配置混合型证券投资基金基金 经理(2015年4月13日起至2016年4月22日 ...

Market Overview - The Hang Seng Index rose 2.4% last week, closing at 22,504 points, recovering most of the losses since the "reciprocal tariffs" were implemented[1] - The Hang Seng Tech Index increased by 5.2%, closing at 5,244 points, with all 12 major sectors in the Hong Kong stock market showing gains[1] - Weekly trading volume decreased by 26.3% to HKD 170.5 billion, and net inflow from the Hong Kong Stock Connect dropped to HKD 1.24 billion[1] Economic Indicators - The global stock markets have largely recovered from the declines following the imposition of tariffs, with cyclical commodities like copper rebounding significantly, while safe-haven assets like gold have seen price declines[1] - Asian currencies showed volatility, with the New Taiwan Dollar rising 4.4% in a single day, and the offshore RMB increasing by 0.92% to 7.21, indicating capital inflow into the region[1] Investment Insights - The current forecasted PE for the Hang Seng Index has risen to 10 times, with risk premiums below one standard deviation of the rolling two-year average, indicating a significant recovery in valuations[2] - The April PMI data from China suggests increasing pressure on manufacturing and service sector activity, which may lead to downward pressure on prices and corporate earnings forecasts[2] Sector Performance - In the automotive sector, BYD's sales increased by 21.3% year-on-year, while Geely's sales rose by 52.7% year-on-year, with most automotive stocks rising between 2% and 7% last week[3] - The healthcare sector saw the Hang Seng Healthcare Index rise by 2.4%, with notable increases in companies like Innovent Biologics and Rongchang Biologics, reflecting strong operational performance[4] Policy and Regulatory Changes - Guangzhou announced a water price increase of up to 93.2%, with residential water prices rising significantly, which may influence water supply industries nationwide[11] - The adjustment in water pricing is expected to support the national water supply industry and may lead to similar price increases in other cities, such as Shenzhen[13]

Market Overview - The Hong Kong stock market is currently lacking direction, with the Hang Seng Index slightly rising by 36 points or 0.2%, closing at 22,008 points, and has been fluctuating around the 22,000 point mark for five consecutive trading days [1] - The Hang Seng Tech Index also saw a minor increase of 0.6%, closing at 5,019 points, maintaining a similar narrow trading range [1] - Recent trading volumes have decreased, with net outflows from the Hong Kong Stock Connect amounting to 6.42 billion HKD, indicating a cautious approach from domestic investors [1] Industry Dynamics Automotive Sector - The automotive sector has reacted positively to news that the U.S. will take measures to alleviate the impact of tariffs on foreign-made cars, leading to a rise in Hong Kong's new energy vehicle stocks [2] - NIO (9866 HK) and Li Auto (2015 HK) saw increases of 2%-5%, while Leap Motor (9863 HK) surged by 8.1% following share purchases by its chairman and existing shareholders [2] - However, XPeng Motors (9868 HK) experienced a decline of 4.4% on the same day [2] Healthcare Sector - The Hang Seng Healthcare Index rose by 1.2%, with WuXi AppTec (2359 HK) reporting a strong first quarter, with revenue and net profit increasing by 21.0% and 89.1% year-on-year, respectively [2] - The company’s core business profitability, reflected in adjusted net profit, saw a 40% year-on-year increase, driven by robust demand for its services from global pharmaceutical companies [2] Energy Sector - The natural gas sector remained stable or slightly increased, benefiting from a decline in overseas natural gas supply prices [3] - Conversely, companies like Longyuan Power (916 HK) and Huaneng International (902 HK) reported disappointing first-quarter results, with declines in power generation and on-grid electricity prices, leading to a drop in their stock prices [3] Real Estate Sector - The new home transaction volume in 30 major cities fell by 23.3% year-on-year, indicating a continued downturn in the real estate market [8] - The Central Political Bureau meeting emphasized the need for timely monetary easing and support for the real estate market, although the effectiveness of such measures remains uncertain [12][14] - The overall performance of Hong Kong-listed property stocks lagged behind the broader market, with the Hang Seng China Mainland Property Index rising only 0.4% [13]

Financial Performance - In 2024, the company achieved a revenue record of RMB 4,052.3 million, representing a year-on-year growth of 90.8%[9] - Gross profit reached RMB 1,239.8 million, a significant increase of 121.6%, with a gross margin of 30.6%[9] - Net profit surged by 277.2% to RMB 1,069.6 million, reflecting operational leverage and strict cost control measures[9] - Revenue for the year ended December 31, 2024, increased by 90.8% to RMB 4,052.3 million[22] - Gross profit for the year ended December 31, 2024, increased by 121.6% to RMB 1,239.8 million[22] - Net profit for the year ended December 31, 2024, increased by 277.2% to RMB 1,069.6 million[22] - Adjusted net profit for the year ended December 31, 2024, increased by 184.8% to RMB 1,174.0 million[22] - The company’s revenue increased by 90.8% from RMB 2,123.8 million for the year ended December 31, 2023, to RMB 4,052.3 million for the year ended December 31, 2024[73] - Adjusted net profit increased by 184.8% from RMB 412.3 million for the year ending December 31, 2023, to RMB 1,174.0 million for the year ending December 31, 2024[95] - Basic earnings per share grew by 217.9% from RMB 0.28 for the year ending December 31, 2023, to RMB 0.89 for the year ending December 31, 2024[96] Operational Expansion - The company expanded its global footprint and enhanced execution capabilities, with significant progress in its first overseas production base in Singapore[7] - The total number of ongoing integrated projects increased from 143 as of December 31, 2023, to 194 as of December 31, 2024[22] - The company is expanding its production capacity and attracting talent to meet the growing demand for bioconjugate drug CRDMO services globally[19] - The company is expanding its production capacity for antibody intermediates in Wuxi, China, and building new facilities in Singapore to meet growing demand for bioconjugate drugs[42] - The new Singapore facility is expected to start operations by the end of 2025, with four production lines planned for clinical and commercial production[45] - The company operates integrated CRDMO services from drug discovery to commercialization across its bases in Shanghai, Wuxi, and Changzhou[42] Research and Development - The proprietary WuXiDARx™ technology has successfully developed 45 preclinical candidates and 7 clinical projects, addressing diverse R&D needs[10] - The company launched innovative linker and payload technologies, including X-LinC, to optimize the therapeutic potential of ADCs[10] - The company is focused on optimizing ADC production processes to ensure consistency and successful scale-up for commercialization[39] - The company plans to submit 30 IND applications in 2024 and deliver over 300 batches of GMP-compliant products[1] - The company aims to enhance its platform to drive the development of the bioconjugate drug industry, benefiting global biopharmaceutical partners and patients[33] Client and Market Growth - The company ranked second globally and first in China in the ADC CRDMO sector based on 2022 revenue, with a strategy focused on empowering and winning molecular partnerships[59] - As of December 31, 2024, the company had 499 clients, a significant increase from 345 in 2023, reflecting a growing and diversified customer base[59] - Revenue from North America grew significantly, contributing RMB 2,030.4 million (50.1% of total revenue) in 2024, compared to RMB 851.9 million (40.1%) in 2023[74] - The company generated RMB 3,767.2 million from ADC projects, accounting for 93.0% of total revenue in 2024, up from 88.9% in 2023[79] Financial Management - Financial costs increased by 331.9% from RMB 0.7 million for the year ending December 31, 2023, to RMB 3.2 million for the year ending December 31, 2024, primarily due to increased interest expenses from bank loans[87] - Other income rose by 149.1% from RMB 92.3 million for the year ending December 31, 2023, to RMB 229.9 million for the year ending December 31, 2024, mainly driven by increased bank interest income[88] - The company maintains a centralized management of financial activities to control and reduce funding costs[111] - The company plans to manage foreign currency risk through forward contracts and hedge accounting for derivatives[120] Sustainability and ESG Commitments - The company implemented strict waste management and emission control standards, contributing to its ESG commitments[11] - The company aims to reduce greenhouse gas emissions by 50% by 2030, using 2021 as the baseline year, while expanding its operations[65] - The company is committed to social responsibility and sustainable growth, with details to be disclosed in its environmental, social, and governance report[199] Governance and Leadership - The board of directors includes experienced professionals with over 20 years in the biotechnology industry, such as Dr. Chen Zhisheng and Dr. Zhou Weichang[141][142] - The company has appointed Ulf Grawunder, an experienced entrepreneur in the life sciences sector, as an independent non-executive director[145] - The company emphasizes the importance of independent judgment in its governance structure, as highlighted by the roles of independent directors[145] - The independent non-executive directors have confirmed their independence as per the listing rules for the fiscal year ending December 31, 2024[165] Risks and Challenges - The company faces significant risks including potential declines in customer spending and demand, which could adversely impact its business, especially given the early-stage development of its products[200] - Increased competition in the industry may lead to customer attrition, affecting the company's market position[200] - The company's growth strategies and business expansion plans may not succeed, which could negatively impact its operations and financial performance[200] - The company may face challenges in successfully developing new technologies and improving existing ones to maintain its competitive edge[200]

Group 1 - The global innovative drug investment and financing environment is recovering, with significant growth in sub-sectors like peptides and ADCs, which is expected to boost the CXO industry's performance [1] - WuXi AppTec reported Q1 2025 revenue of approximately 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit of about 3.672 billion yuan, up 89.06% year-on-year [1] - The Hong Kong innovative drug sector is experiencing a significant valuation correction, with the Hong Kong innovative drug index's P/E ratio dropping from 64 times to 27 times in less than two months, indicating attractive investment opportunities [1] Group 2 - The Hong Kong innovative drug ETF (159567) tracks the National Securities Hong Kong Stock Connect Innovative Drug Index, which has a 90% weight in innovative drug companies, positioning it to benefit from trends like AI-enabled drug development and the expansion of domestic innovative drugs [2] - The innovative drug ETF (159992) tracks an index that includes leading companies in the innovative drug industry chain, benefiting from AI advancements and new healthcare policies aimed at supporting innovative drugs [2] - Policies from Beijing and Shenzhen are promoting the development of innovative drugs and devices, focusing on R&D innovation, clinical trials, and regulatory approvals, which will enhance the competitiveness of innovative drug companies [2]

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]

本文约 2 5 0 0 字，推荐阅读时长 1 5 分钟，欢迎关注新财富公众号。 1 引言 4月14日，美国商务部宣布启动对进口药品的国家安全调查。这一调查覆盖了所有进口药品，包括成 品仿制药、原研药以及用于生产这些药品的关键药用成分。此举属于特朗普政府根据1962年《贸易扩 展法》第232条对多个行业进行的关税调查的一部分。虽然调查尚未结束，预计结果将在270天内公 布，但业内普遍认为，这将赋予特朗普政府对进口药品和原料药征收关税的权力。特别是对中国等主 要药品出口国的影响，可能会带来严重的供应链中断及成本上升。 事实上，美国每年从中国进口药品总额约60亿美元，其中大量为抗生素、抗病毒及心血管药物等基础 药物。一旦关税进一步扩大实施，这些进口药品的成本预计将明显上升，对美国本土药品生产商带来 直接冲击。为应对这种风险，特朗普政府提出多项措施推动产业本土化。 分析师预计，如果对来自中国的API征收10%的关税，仿制药企业的利润将下跌2%-3%，创新药利润 下跌可能更严重。 2 美国关税筑墙， 中概股 跌宕 自2025年特朗普重新执政以来，美国政府出台了一系列针对生物医药产业的重要政策，核心目标是强 化美国医药产 ...

Group 1 - The core point of the article highlights the performance of the China Europe Medical Innovation Stock C fund, which has a latest net value of 1.1626 yuan, reflecting a decrease of 1.43% [1] - The fund's performance over the past month shows a return of 3.72%, ranking 37 out of 541 in its category; over the past three months, it has achieved a return of 20.12%, ranking 10 out of 539; and since the beginning of the year, it has returned 17.16%, ranking 13 out of 537 [1] - The top ten holdings of the fund account for a total of 75.62%, with significant positions in companies such as WuXi AppTec (10.35%), Kelun-Biotech (10.15%), and WuXi Biologics (9.82%) [1] Group 2 - The China Europe Medical Innovation Stock C fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at Guotai Junan Securities and Minsheng Zhiyin Fund Management [2]

AI基金东吴医疗服务股票A（013940）披露2025年一季报，第一季度基金利润719.02万元，加权平均基金份额本期利润0.0918元。报告期内，基金净值增长 率为18.83%，截至一季度末，基金规模为4473.8万元。 该基金属于标准股票型基金，长期投资于医药医疗股票。截至4月23日，单位净值为0.583元。基金经理是毛可君，目前管理3只基金。其中，截至4月23日， 东吴医疗服务股票A近一年复权单位净值增长率最高，达17.37%；东吴双三角股票A最低，为-8.68%。 基金管理人在一季报中表示，展望后市，短期来看，国际贸易博弈对市场或有较大冲击，避险情绪或阶段性主导，但中长期看我们依然相对看好我国创新药 为代表的的医药产业发展趋势。 截至4月23日，东吴医疗服务股票A近三个月复权单位净值增长率为17.18%，位于同类可比基金19/54；近半年复权单位净值增长率为8.09%，位于同类可比 基金12/54；近一年复权单位净值增长率为17.36%，位于同类可比基金11/54；近三年复权单位净值增长率为-26.68%，位于同类可比基金36/46。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基金业绩比 ...

【解剖大盘】 关税战终于出现缓和迹象，美股有望二次探底成功，港股今天也跳空高开，全天走势平稳，收盘涨 2.37%，恒指站上了22000点关口。 现在的美股已经到了危险的边缘，如果再跌破近期的低点，后果非常严重，资金的外逃将不可避免。全 球资管巨头骏利亨德森投资公司目前正考虑减少其对美国资产的敞口。大概会有10%的资金或转移到欧 洲、中国、中东和拉丁美洲。这还只是开始，稳不住的话，出逃的比例恐怕会更多。全球资金总量是有 限的，此消彼长也是必然的趋势。看下新兴市场，印度上周成为首个抹平关税引发的跌幅的主要市场， MSCI新兴市场指数周三上涨1.7%，韩国KOSPI指数收复了因美国征收对等关税而导致的跌幅。中国市 场也很接近了。 再看一下基本面状况，据报中方禁韩企向美国国防部门出口含中国稀土产品，这就是防止出现钻漏洞的 情况，我们这一块具有丰富的经验，连马斯克都在担心其擎天柱机器人要用到的稀土永磁材料会被禁。 金力永磁(06680)今天也借机涨超12%，光是稀土一项，美国军工企业就非常难受，高精尖武器就无法继 续生产，军工复合体不慌是假的。还有，据媒体4月23日报道称，美国高关税迫使中国买家用中东的 LPG取代美国 ...